Mitsui and R-Pharm partnership is among the achievements of Russia-Japan cooperation plan

May 31

Marking the Russia-Japan cultural exchange year two countries are ready to announce preliminary achievements of implementation of 8-point Cooperation Plan coined during the meeting of Russian president Vladimir Putin and Japanese Prime Minister Shinzo Abe in May 2016 in order to strengthen bilateral relations. Among other projects that are aimed at development of healthcare, medicine and pharmaceutical industry, Mitsui & Co., Ltd. (“Mitsui”) and R-Pharm partnership is considered to be worthy of such an honorable mention.

By utilizing Mitsui’s experience R-Pharm will be able to increase its technological and exporting capabilities. Cooperation of two companies will lead to the introduction of new modern medicines onto the Russian market.

Mitsui’s Pharmaceutical Business Division GM Masanobu Suzuki commented that “We consider Russian pharmaceutical market attractive from many perspectives, and expect continued demand growth in high-quality medicines, especially for treatment of cancer, diabetes and other lifestyle-related diseases. Mitsui will continue to support R-Pharm activities to introduce innovative medicines to Russian market and contribute to better health in Russia.”

 “When it comes to pharmaceuticals, health care and highly technological medicine, Japan is undoubtedly one of the leading countries of the world. That is why our partnership with Mitsui is so important. It fully corresponds to the development strategy of our company. This cooperation will help to expand our reach in the international market as well as localize facilities for production of foreign medicines in Russia”, said R-Pharm CEO Vasily Ignatiev.

Stages of business deal:

•On December 16, 2016 (Tokyo, Japan), R-Pharm and Mitsui signed the memorandum of cooperation in the presence of the President of the Russian Federation Vladimir Putin and the Prime Minister of Japan Shinzo Abe.

•On April 27, 2017 (Moscow, Russia), Mitsui entered into an agreement for an acquisition of the shares of R-Pharm.

•On October 17, 2017 (Moscow, Russia), Mitsui bought  10% of R-Pharm company shares, thus successfully closing the deal.

About Mitsui:

Mitsui is a global trading and investment company headquartered in Japan that is actively working in the broad areas of business all over the world. Today Mitsui is the largest Japanese investor in the Russian market. By now Mitsui has invested over three billion US dollars in Russian economy. Mitsui has been working in Russia over 50 years as one of priority countries in its investment strategy.

Other company news

06 November 2018 – R-Pharm Group and the Specialty Pharma Company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard:...
read more...
November 6
The IV Eurasian Rheumatology Congress attended by leading healthcare professionals from around the globe was held in Moscow on 26-28...
read more...
September 28
Localization of full cycle production of Kaletra® finished dosage form will help to improve access of Russian patients to antiretroviral...
read more...
July 4